Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Related Experiment Video
Updated: May 9, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
Sabrina Kermiche-Rahali1, Aude Di Fiore, Fanny Drieux
1Department of Digestive Surgery, Rouen University Hospital, 1 Rue de Germont, 76031 Rouen, France.
Abstract:
Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.
Related Concept Videos
Portal Hypertension
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...
